{
  "docId": "019de075-f154-767b-9f07-479a2da3f64b",
  "docSlug": "d4796e91221d5758021de97ee63957e0",
  "documentTitle": "Exscientia | Investor Presentation Deck | 69 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 56,
  "pageCount": 69,
  "prevPage": 55,
  "nextPage": 57,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a split-layout to contrast current operational status with overall program value proposition.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f154-767b-9f07-479a2da3f64b/56",
  "deckHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b",
  "deckJsonHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b.json",
  "deckAnchorHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b#slide-56",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.49,
        "y": 0.3
      },
      "kind": "list",
      "text": "Potent, highly selective, reversible and brain penetrant LSD1 inhibitor; Suitable therapeutic index established with no unexpected toxicity in non-GLP studies; Potential in broad range of haematologic and oncologic diseases; Potential as monotherapy or combination therapy; Translational work ongoing to define optimal patient populations and validation of PD biomarkers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd16df07-36f5-4bca-9450-b14f4ed7fc63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.38,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "list",
      "text": "GLP-tox studies ongoing; CMC work underway; MIDD to define best dose and dosing regimen",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df4c261f-c0d1-475b-a3dd-2aa0867311e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "paragraph",
      "text": "MIDD = Model-informed Drug Development",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8bfc9bba-9a1e-4176-80b1-d595f1c688db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.49,
        "y": 0.23
      },
      "kind": "title",
      "text": "Programme Highlights:",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "889dfa03-2208-49ad-a443-0a2fc0eb3266",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.25,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "539: Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f42f62d1-b5c8-4679-b6d1-1fd2b29784d3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "eb19722c-5c26-4120-95aa-9e690bdf9f5f",
      "evidence": "The slide presents a summary of key points, which is a clear executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 69,
      "from": 8,
      "beatId": "96bf0b4a-a49b-4aee-bb3c-8a6ad1f87eda",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents Exscientia's solution, highlighting its AI-driven platform and its potential to improve clinical trial success rates.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 69,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "89204827-3a6d-41c5-9676-a9c3c4bc7a6d",
      "evidence": "The deck presents Exscientia's approach to precision medicine, highlighting its effectiveness.",
      "position": 1,
      "objective": "Why is Exscientia's approach to precision medicine effective?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}